Larvol Delta - MSU42011-alone-and-in-combination-with-selumetinib-reduces-pERK-levels-in-NF1-cancer-cells-and-decreases-CCL2-expression-in-THP1-macrophages

MSU-42011 - Akeila Bio, Michigan State University

Koselugo (selumetinib) - Merck (MSD), AstraZeneca

https://www.abstractsonline.com/pp8/#!/10828/presentation/7315

Pei-Yu Hung; Lizbeth Lockwood; Karen T. Liby

Mar 14, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next